ENVB - Enveric Biosciences, Inc. Stock Price, Fair Value and News

$6.00+0.18 (+3.09%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ENVB Price Action

Last 7 days

3.8%

Last 30 days

-15.2%

Last 90 days

-50.5%

Trailing 12 Months

-99.3%

ENVB RSI Chart

ENVB Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.37

Price/Sales (Trailing)

0.09

EV/EBITDA

-0.08

Price/Free Cashflow

-0.47

ENVB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ENVB Fundamentals

ENVB Revenue

Revenue (TTM)

35.4M

ENVB Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

10.09%

Earnings Growth (Qtr)

25.62%

ENVB Profitability

Operating Margin

20.66%

EBT Margin

-27.47%

Return on Equity

-281.6%

Return on Assets

-223.12%

Free Cashflow Yield

-214.08%

ENVB Investor Care

Shares Dilution (1Y)

980.51%

Diluted EPS (TTM)

-81.13

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	38.8M	36.1M	35.4M	0
2019	42.6M	42.6M	41.1M	39.9M
2018	47.3M	46.1M	44.2M	43.0M
2017	41.5M	47.1M	49.5M	48.6M
2016	23.0M	25.7M	31.3M	36.1M
2015	16.8M	16.8M	16.9M	20.4M
2014	6.1M	11.5M	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

CEO	Dr. Joseph Edward Tucker Ph.D.
WEBSITE	enveric.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	25

Enveric Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Enveric Biosciences, Inc.? What does ENVB stand for in stocks?

ENVB is the stock ticker symbol of Enveric Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enveric Biosciences, Inc. (ENVB)?

As of Wed Dec 03 2025, market cap of Enveric Biosciences, Inc. is 3.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENVB stock?

You can check ENVB's fair value in chart for subscribers.

Is Enveric Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENVB is over valued or under valued. Whether Enveric Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Enveric Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENVB.

What is Enveric Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ENVB's PE ratio (Price to Earnings) is -0.37 and Price to Sales (PS) ratio is 0.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENVB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enveric Biosciences, Inc.'s stock?

In the past 10 years, Enveric Biosciences, Inc. has provided -0.808 (multiply by 100 for percentage) rate of return.